STIOLTO RESPIMAT
LAMALABA SMI
Tiotropium bromide / Olodaterol · Boehringer Ingelheim
Active Medication & Mechanism
- Tiotropium bromide monohydrate LAMA2.5 mcg per actuation
Long-acting muscarinic antagonist. Blocks M3 receptors on airway smooth muscle with slow dissociation, providing 24-hour bronchodilation.
- Olodaterol hydrochloride LABA2.5 mcg per actuation
Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation (24 hours) through selective beta2-receptor stimulation on airway smooth muscle.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 2.5/2.5 mcg | Adults (≥18 years) | 2 puffs (5/5 mcg total) once daily at the same time each day Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. | 5/5 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Stiolto Respimat is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute bronchospasm. Use a SABA. |